Last reviewed: June 23, 2026
Last updated: June 23, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide and other GLP-1 receptor agonists are powerful tools for weight loss and metabolic health, but pregnancy changes the risk-benefit calculation significantly. Current clinical evidence and regulatory guidance indicate that stopping semaglutide before conception is the safest approach for women planning to have children.
Is Semaglutide Safe During Pregnancy?
The FDA has not approved semaglutide for use during pregnancy, and animal reproduction studies have raised safety concerns. Rodent studies at high doses showed delayed fetal skeletal development and increased fetal loss, though these animal models do not always predict human outcomes. The lack of adequate human pregnancy data means healthcare providers cannot confidently guarantee fetal safety, making avoidance the standard recommendation.
Limited case reports from women who became pregnant while using semaglutide have not identified clear patterns of harm, but these observations are too sparse to establish a safety profile. Pregnancy is a period of rapid physiological change, and GLP-1 medications alter glucose metabolism, appetite signaling, and gastric emptying—effects that may interact unpredictably with pregnancy hormones and fetal development. Most expert guidelines recommend discontinuing semaglutide at least one month before attempting conception.
Potential Risks of GLP-1 Use in Early Pregnancy
Semaglutide slows gastric emptying and reduces nutrient absorption, potentially affecting the delivery of essential calories, protein, and micronutrients critical for early fetal development. During the first trimester, when organ systems are forming, any disruption to maternal nutrition or blood glucose stability could theoretically increase miscarriage risk or birth defects, though direct causation has not been proven in humans. Nausea and loss of appetite caused by semaglutide might also compound the nutritional challenges that some pregnant women already experience.
GLP-1 medications lower blood sugar levels, and tight glycemic control in pregnancy requires careful monitoring to avoid both hyperglycemia and hypoglycemia. If a woman became pregnant while on semaglutide and experienced unmanaged blood sugar fluctuations, fetal complications including neural tube defects and growth problems could result. This additional layer of metabolic risk is why preconception planning—including switching to safer diabetes or weight management strategies—is essential.
Planning Pregnancy While on Semaglutide Therapy
Women who are taking semaglutide and considering pregnancy should have a detailed conversation with both their weight loss provider and obstetrician at least three months before attempting conception. This timeline allows for gradual medication discontinuation, reassessment of blood glucose control, and optimization of nutrition and weight status before conception. A preconception checkup can identify other risk factors—such as polycystic ovary syndrome (PCOS) or insulin resistance—that might benefit from alternative management strategies during pregnancy.
After stopping semaglutide, weight regain is common over several months, which can increase pregnancy complications like gestational diabetes and preeclampsia. Some women benefit from lifestyle-focused interventions, structured meal planning, or consultation with a registered dietitian to maintain metabolic health during the preconception window and throughout pregnancy. PlexusDx providers can help design a personalized transition plan that prioritizes both maternal health and fetal safety.
What Happens If You Become Pregnant While Taking Semaglutide?
If pregnancy is confirmed while a woman is taking semaglutide, the medication should be stopped immediately and a healthcare provider should be notified without delay. Early notification allows for detailed ultrasound evaluation, genetic counseling if desired, and close monitoring of fetal development to watch for any signs of developmental delay or anomalies. Most pregnancies that began with unplanned semaglutide exposure have resulted in healthy deliveries, but individualized monitoring remains important.
After discontinuation, prenatal care should include frequent blood glucose monitoring, nutritional assessment, and fetal growth tracking via ultrasound at standard intervals. Some women will transition to insulin therapy if blood sugar management during pregnancy becomes challenging, while others rely on dietary and lifestyle modifications. The obstetric team will determine the safest approach based on the woman's metabolic status and pregnancy risk factors.
Postpartum Weight Management After Semaglutide Pause
Once pregnancy and breastfeeding are complete, women may resume semaglutide or switch to alternative GLP-1 medications like tirzepatide, depending on their goals and clinical history. PlexusDx offers multiple GLP-1 formulations—including compounded semaglutide injection starting at $149/month—to match individual preferences and metabolic needs after the postpartum period. Many women find that resuming structured weight management therapy helps prevent excessive weight retention and supports long-term metabolic health.
Breastfeeding mothers should discuss medication safety with their pediatrician, as small amounts of GLP-1 medications may pass into breast milk. Current evidence suggests that exposure through breast milk is unlikely to harm infants, but individual risk assessment is warranted. PlexusDx providers can coordinate care with obstetric and pediatric teams to support safe resumption of therapy when nursing is complete or when individual circumstances permit.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I use semaglutide if I'm trying to get pregnant?
Semaglutide should be stopped at least one month before attempting conception due to limited human safety data and animal studies suggesting potential fetal risks. A preconception consultation with your healthcare provider will help establish a personalized timeline for discontinuation and alternative weight management strategies during the pregnancy-planning phase.
What does the clinical evidence say about GLP-1 medications and birth defects?
Animal studies at high semaglutide doses showed delayed skeletal development and increased fetal loss in rodents, but human pregnancy data remains very limited. Several case reports of unplanned pregnancies during semaglutide use have not identified clear patterns of congenital anomalies, but this sample size is too small to establish definitive safety, which is why regulatory agencies recommend avoidance.
How much does it cost to restart semaglutide after pregnancy?
PlexusDx compounded semaglutide injection starts at $149 per month with a flat monthly price that does not change with dose increases—your dose may go up, but your price won't. All medications come from licensed 503A compounding pharmacies, require no insurance, and are HSA/FSA eligible for postpartum resumption.
Is it safe to breastfeed while taking semaglutide?
Current evidence suggests that small amounts of GLP-1 medications pass into breast milk at levels unlikely to harm nursing infants, but individual risk assessment by your pediatrician and prescriber is recommended. Delaying resumption of semaglutide until weaning is complete eliminates any theoretical exposure risk if breastfeeding is a priority.
Can genetic testing help me understand my risk for pregnancy complications related to weight?
PlexusDx Precision Peptide Genetic Test identifies variants in GLP1R, GIPR, FTO, and MC4R genes that influence appetite, metabolism, and weight regulation across 14 pathways and 49 peptides. Understanding your genetic predispositions can help your healthcare team develop safer preconception and postpartum weight management strategies tailored to your biology; the test is available as a $99 add-on after your first month of treatment.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Navigating Calorie Intake on Ozempic: Understanding Your Body’s Needs for Sustainable Weight Loss
How Soon Do You Feel Side Effects from Ozempic?